department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Ibrance · pharmadog

pharmadog
drugs
Ibrance

drug

patient view →

palbociclib

Marketedupdated 2mo ago

by $OTLC Oncotelic Therapeutics, Inc.

Approved

annual revenue · 2024–2024peak $4.4B

community read0 votes

indications

investigational

Breast Cancer

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Ibrance

generic

palbociclib

indication

Breast Cancer

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 40m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 5, 2027

241 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (30)

Feb 19, 2037patentUS 11065250*PED
Feb 19, 2037patentUS 11065250*PED
Feb 19, 2037patentUS 11065250*PED
Aug 19, 2036formulationUS 11065250
Aug 19, 2036formulationUS 11065250
Aug 19, 2036formulationUS 11065250
Aug 8, 2034patentUS 10723730*PED
Aug 8, 2034patentUS 10723730*PED
Aug 8, 2034patentUS 10723730*PED
Aug 8, 2034patentUS 10723730*PED
Aug 8, 2034patentUS 10723730*PED
Aug 8, 2034patentUS 10723730*PED
Feb 8, 2034compositionUS 10723730
Feb 8, 2034compositionUS 10723730
Feb 8, 2034compositionUS 10723730
Feb 8, 2034compositionUS 10723730
Feb 8, 2034compositionUS 10723730
Feb 8, 2034compositionUS 10723730
Sep 5, 2027patentUS RE47739*PED1.2y
Sep 5, 2027patentUS RE47739*PED1.2y
Sep 5, 2027patentUS RE47739*PED1.2y
Sep 5, 2027patentUS RE47739*PED1.2y
Sep 5, 2027patentUS RE47739*PED1.2y
Sep 5, 2027patentUS RE47739*PED1.2y
Mar 5, 2027compositionUS RE47739241d
Mar 5, 2027compositionUS RE47739241d
Mar 5, 2027compositionUS RE47739241d
Mar 5, 2027compositionUS RE47739241d
Mar 5, 2027compositionUS RE47739241d
Mar 5, 2027compositionUS RE47739241d

FDA exclusivities (12)

Mar 16, 2029PEDPediatric (6mo bonus)2.7y
Mar 16, 2029PEDPediatric (6mo bonus)2.7y
Mar 16, 2029PEDPediatric (6mo bonus)2.7y
Mar 16, 2029PEDPediatric (6mo bonus)2.7y
Mar 16, 2029PEDPediatric (6mo bonus)2.7y
Mar 16, 2029PEDPediatric (6mo bonus)2.7y

Sep 16, 2028

M-14

Method (3y)

2.2y

Sep 16, 2028M-14Method (3y)2.2y

Sep 16, 2028M-14Method (3y)2.2y

Sep 16, 2028M-14Method (3y)2.2y

Sep 16, 2028M-14Method (3y)2.2y

Sep 16, 2028M-14Method (3y)2.2y

🐶 often sniffed alongside

top 2

company$PFEPFIZER INC1 co-mentions · 1 sources
tagDrug Shortage1 co-mentions · 1 sources

Trials studying palbociclib

phase1A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumorsrecruitingn=234
phase3A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Canceractive not recruitingn=325
phase2Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Canceractive not recruitingn=435
phase1To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Canceractive not recruitingn=200
phase2A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumorsactive not recruitingn=176
phase2First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumorsrecruitingn=880
phase3BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Diseaserecruitingn=1,056
phase2TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancerrecruitingn=4,200

more trials →